Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jennifer L. Schwartz is active.

Publication


Featured researches published by Jennifer L. Schwartz.


Cancer | 2009

The atypical Spitz tumor of uncertain biologic potential

Mathew W. Ludgate; Douglas R. Fullen; Julia Lee; Lori Lowe; Carol R. Bradford; James D. Geiger; Jennifer L. Schwartz; Timothy M. Johnson

Atypical Spitz tumors (AST) are rare spitzoid melanocytic proliferations with an uncertain malignant potential. ASTs have overlapping features of both Spitz nevi and spitzoid melanoma, and consequently generate controversy with diagnosis and management. Sentinel lymph node biopsy (SLNB) has been proposed as a possible means to gain additional insight into the true biologic potential of these tumors; however, previous reports on the use of SLNB in ASTs have been limited by small numbers of patients and short durations of follow‐up.


Journal of Clinical Oncology | 2011

Features Predicting Sentinel Lymph Node Positivity in Merkel Cell Carcinoma

Jennifer L. Schwartz; Kent A. Griffith; Lori Lowe; Sandra L. Wong; Scott A. McLean; Douglas R. Fullen; Christopher D. Lao; James A. Hayman; Carol R. Bradford; Riley S. Rees; Timothy M. Johnson; Christopher K. Bichakjian

PURPOSE Merkel cell carcinoma (MCC) is a relatively rare, potentially aggressive cutaneous malignancy. We examined the clinical and histologic features of primary MCC that may correlate with the probability of a positive sentinel lymph node (SLN). METHODS Ninety-five patients with MCC who underwent SLN biopsy at the University of Michigan were identified. SLN biopsy was performed on 97 primary tumors, and an SLN was identified in 93 instances. These were reviewed for clinical and histologic features and associated SLN positivity. Univariate associations between these characteristics and a positive SLN were tested for by using either the χ(2) or the Fishers exact test. A backward elimination algorithm was used to help create a best multiple variable model to explain a positive SLN. RESULTS SLN positivity was significantly associated with the clinical size of the lesion, greatest horizontal histologic dimension, tumor thickness, mitotic rate, and histologic growth pattern. Two competing multivariate models were generated to predict a positive SLN. The histologic growth pattern was present in both models and combined with either tumor thickness or mitotic rate. CONCLUSION Increasing clinical size, increasing tumor thickness, increasing mitotic rate, and infiltrative tumor growth pattern were significantly associated with a greater likelihood of a positive SLN. By using the growth pattern and tumor thickness model, no subgroup of patients was predicted to have a lower than 15% to 20% likelihood of a positive SLN. This suggests that all patients presenting with MCC without clinical evidence of regional lymph node disease should be considered for SLN biopsy.


Journal of The American Academy of Dermatology | 2003

Placental metastasis of maternal melanoma.

Jamie F. Altman; Lori Lowe; Bruce G. Redman; Peg Esper; Jennifer L. Schwartz; Timothy M. Johnson; Hope K. Haefner

Metastasis of maternal malignant tumor to the products of conception is a rare event. Melanoma is the most common maternal malignant tumor to metastasize to the placenta and the fetus. We report the case of a 28-year-old woman with melanoma during pregnancy. At parturition, histologic evaluation of the placenta revealed metastatic melanoma, and multiple organ metastasis developed. The infant was free of disease. Metastasis to products of conception portends a poor prognosis for the mother. To our knowledge, this report is the first of a patient with melanoma metastasis to the placenta to survive more than 7 months after parturition. As caretakers of patients with melanoma, dermatologists are in a position to coordinate and direct the care and follow-up treatment of affected patients.


human factors in computing systems | 2003

Strategy hubs: next-generation domain portals with search procedures

Suresh K. Bhavnani; Bichakjian K. Christopher; Timothy M. Johnson; Roderick J. A. Little; Frederick A. Peck; Jennifer L. Schwartz; Victor J. Strecher

Current search tools on the Web, such as general-purpose search engines (e.g. Google) and domain-specific portals (e.g. MEDLINEplus), do not provide search procedures that guide users to form appropriately ordered sub-goals. The lack of such procedural knowledge often leads users searching in unfamiliar domains to retrieve incomplete information. In critical domains such as in healthcare, such ineffective searches can have dangerous consequences. To address this situation, we developed a new type of domain portal called a Strategy Hub. Strategy Hubs provide the critical search procedures and associated high-quality links that enable users to find comprehensive and accurate information. This paper describes how we collaborated with skin cancer physicians to systematically identify generalizeable search procedures to find comprehensive information about melanoma, and how these search procedures were made available through the Strategy Hub for healthcare. A pilot study suggests that this approach can improve the efficacy, efficiency, and satisfaction of even expert searchers. We conclude with insights on how to refine the design of the Strategy Hub, and how it can be used to provide search procedures across domains.


Pediatric Blood & Cancer | 2005

High-risk surgically resected pediatric melanoma and adjuvant interferon therapy.

Mwe Mwe Chao; Jennifer L. Schwartz; Daniel S. Wechsler; Courtney D. Thornburg; Kent A. Griffith; James A. Williams

Pediatric patients with high‐risk surgically resected melanoma are at risk for relapse, yet little is known about these young patients and how they tolerate high‐dose interferon therapy.


Annals of Surgical Oncology | 2006

Significance of Multiple Lymphatic Basin Drainage in Truncal Melanoma Patients Undergoing Sentinel Lymph Node Biopsy

Jonathan B. McHugh; Lyndon D. Su; Kent A. Griffith; Jennifer L. Schwartz; Sandra L. Wong; Vincent M. Cimmino; Alfred E. Chang; Timothy M. Johnson; Michael S. Sabel

BackgroundTruncal melanoma involving metastases to multiple lymph node basins has a much worse prognosis than tumor involvement of a single lymph node basin. Recent results also suggest that, independently of the status of lymph node involvement, patients with multiple lymphatic basin drainage (MLBD) on lymphoscintigraphy have an increased risk of lymph node metastasis and a worse prognosis than those with a single lymphatic drainage basin. Because published reports have conflicting results, the authors compared their experience at the University of Michigan Comprehensive Cancer Center with recently published findings.MethodsThe authors searched a prospectively maintained melanoma database at the University of Michigan for patients with primary truncal melanoma who underwent lymphoscintigraphy and sentinel lymph node biopsy between 1997 and 2004. The association of MLBD with the clinical and pathologic characteristics collected and the presence of regional metastases was tested by using contingency tables and the χ2 test statistic and by using the Fisher’s exact test statistic when cell frequencies were small. The product-limit method of Kaplan and Meier was used to estimate disease-free and overall survival probabilities.ResultsOf 423 patients with primary truncal melanoma who underwent sentinel lymph node biopsy, 123 (29%) had a positive result, and 98 patients (23.2%) had MLBD. Patients with tumors located in the middle of the trunk and tumor ulceration were more likely to have MLBD (P < .0001 and P = .045, respectively). Patients with a single lymphatic drainage basin and MLBD had a similar risk of lymph node metastasis and similar disease-free and overall survival.ConclusionsPatients with truncal melanomas tend to have MLBD when the tumor is located in the middle of the trunk or when ulceration is present. In our experience, drainage to multiple lymphatic basins was not an independent risk factor for sentinel lymph node metastasis and has no independent prognostic significance.


Journal of Lower Genital Tract Disease | 2004

Vulvar melanoma: review of diagnosis, staging, and therapy.

Mary Ellen Wechter; R. Kevin Reynolds; Hope K. Haefner; Lori Lowe; Stephen B. Gruber; Jennifer L. Schwartz; Carolyn Johnston; Timothy M. Johnson

Objectives. To update, assimilate, and bridge the contemporary literature on vulvar and cutaneous melanoma regarding diagnosis, staging, and therapy to provide a useful clinical reference for managing and counseling for affected patients. Materials and Methods. A computerized search for reports in the literature up to June 2003 was carried out using PubMed and MEDLINE databases. Multidisciplinary involvement was used in evaluating the available data and formulating conclusions. Results. More than 300 reports were reviewed. Diagnosis, staging, and therapy aspects of vulvar melanoma are summarized. Conclusions. Vulvar melanoma represents a subtype of cutaneous melanoma, with similar prognostic and staging factors. The most recent American Joint Committee on Cancer staging system for cutaneous melanoma is applicable to vulvar melanoma. Sentinel lymph node biopsy is reliable for staging the regional lymph node basin for vulvar melanoma. Standardized documentation of clinical and histopathologic parameters is needed to standardize grouping of cases for future comparison studies.


Journal of The American Academy of Dermatology | 2013

Management options for metastatic melanoma in the era of novel therapies: A primer for the practicing dermatologist : Part II: Management of stage IV disease

Matthew C. Fox; Christopher D. Lao; Jennifer L. Schwartz; Marcus L. Frohm; Christopher K. Bichakjian; Timothy M. Johnson

Part II of this continuing medical education article will discuss the treatment options for stage IV melanoma, including novel therapies, such as ipilimumab and vemurafenib; established therapies, including high-dose interleukin-2, conventional chemotherapy, and biochemotherapy; and additional therapies currently under investigation in the form of clinical trials. The approach to patients with brain metastases will be discussed, as will recommendations for distress screening and defining aspects of palliative care.


JAMA Dermatology | 2016

Recurrence and Survival in Patients With Merkel Cell Carcinoma Undergoing Surgery Without Adjuvant Radiation Therapy to the Primary Site.

Marcus L. Frohm; Kent A. Griffith; Kelly L. Harms; James A. Hayman; Douglas R. Fullen; Christine C. Nelson; Sandra L. Wong; Jennifer L. Schwartz; Christopher K. Bichakjian

IMPORTANCE The use of adjuvant radiation therapy (RT) to the primary site in Merkel cell carcinoma (MCC) is not uncommon. However, the need for adjuvant RT to the primary site in patients at low risk for local recurrence is questionable. OBJECTIVES To examine the occurrence of true local, satellite, in-transit, regional, and distant recurrences in patients undergoing surgery alone without adjuvant RT to the primary site. To establish overall survival (OS), MCC-specific survival (MCCSS), and disease-free survival (DFS) relationships in a cohort of patients with MCC. DESIGN, SETTING, AND PARTICIPANTS Our University of Michigan Multidisciplinary MCC Program database was used to obtain characteristics and outcome measures for 104 patients (105 primary MCCs) with tumors less than 2 cm in diameter. The majority of patients were treated between July 2006 and November 2012. MAIN OUTCOMES AND MEASURES Outcome measures included the occurrence of true local, satellite, in-transit, regional, and distant recurrences. End points included OS, MCCSS, and DFS. RESULTS Overall, information for 55 men and 49 women with 105 primary MCCs was obtained; 19 patients developed recurrent disease, and the mean time to first recurrence was 10.7 months. True local recurrence occurred in 1 patient with concurrent in-transit recurrence. Satellite recurrence occurred in 1 patient with concurrent regional recurrence. Four additional patients developed in-transit metastases. Thirteen patients had a regional recurrence component, 4 patients had distant metastases, and 6 patients developed subsequent regional and/or distant recurrences. Stratified by initial pathologic stage, the OS and MCCSS at 48 months were estimated to be 85.0% (95% CI, 71.8%-92.3%) and 94.4% (95% CI, 83.4%-98.2%) for patients with stage 1A/B disease and 63.2% (95% CI, 36.6%-81.1%) and 78.1% (95% CI, 50.0%-91.5%) for patients with stage 3A disease. The OS and MCCSS at 24 months for patients with stage 3B disease were both 50.0% (95% CI, 5.8%-84.5%). CONCLUSIONS AND RELEVANCE In selected MCC patients with primary tumors less than 2 cm in diameter treated with surgery alone without adjuvant RT to the primary site, we found a low occurrence of true local recurrences and satellite recurrences. This relatively low rate of local recurrence questions the need for adjuvant RT to the primary tumor site in patients with small low-risk lesions.


JAMA Dermatology | 2017

Efficacy of Staged Excision With Permanent Section Margin Control for Cutaneous Head and Neck Melanoma

Jeffrey S. Moyer; Shannon Rudy; Philip S. Boonstra; Casey T. Kraft; Steven B. Chinn; Shan R. Baker; Jennifer L. Schwartz; Christopher K. Bichakjian; Douglas R. Fullen; Alison B. Durham; Lori Lowe; Timothy M. Johnson

Importance Melanoma arising in chronically photodamaged skin, especially on the head and neck, is often characterized by poorly defined clinical margins and unpredictable occult extension. Staged excision techniques have been described to treat these challenging melanomas. Objective To investigate the local recurrence rates and margin to clearance end points using staged excision with comprehensive hematoxylin-eosin–stained permanent section margin control. Design, Setting, and Participants In this observational cohort study performed from October 8, 1997, to December 31, 2006, with a median follow-up of 9.3 years, 806 patients with melanoma on the head and neck, where clinical occult extension is common, were studied at an academic medical center. Interventions Staged excision with comprehensive hematoxylin-eosin–stained permanent section margin control commonly known as the square technique. Main Outcomes and Measures Local recurrence rates and margin to clearance end points. Results A total of 806 patients (276 women [34.2%]; 805 white [99.9%]) with a median age at the time of first staged excision procedure of 65 years (range, 20-94 years) participated in the study. The estimated local recurrence rates were 1.4% at 5 years, 1.8% at 7.5 years, and 2.2% at 10 years. For each 50-mm2 increase in the size of the clinical lesion, there was a 9% increase in the rate of local recurrence (hazard ratio, 1.09; 95% CI, 1.02-1.15; P = .02). The mean (SD) margin from lesion to clearance for melanoma in situ was 9.3 (5.1) mm compared with 13.7 (5.9) mm for invasive melanoma. For melanoma in situ, margins were clear after 5 mm or less in 232 excisions (41.1%) and after 10 mm or less in 420 excisions (74.5%). For invasive melanoma, margins were clear after 5 mm or less in 8 excisions (3.0%) and after 10 mm or less in 141 excisions (52.2%). Conclusions and Relevance Staged excision with comprehensive permanent section margin control of melanomas arising in chronically sun-damaged skin on the head and neck has favorable recurrence rates when melanoma margins are difficult to assess, and recurrence rates are high with traditional techniques.

Collaboration


Dive into the Jennifer L. Schwartz's collaboration.

Top Co-Authors

Avatar

Timothy M. Johnson

Fred Hutchinson Cancer Research Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lori Lowe

University of Michigan

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Stephen B. Gruber

University of Southern California

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge